- Open Access
Delta-like 4 mRNA is regulated by adjacent natural antisense transcripts
Vascular Cell volume 7, Article number: 3 (2015)
Recent evidence suggests that a majority of RNAs in the genome do not code for proteins. They are located in the sense (S) or antisense (AS) orientation and, to date, the functional significance of these non-coding RNAs (ncRNAs) is poorly understood. Here, we examined the relationship between S and AS transcripts in the regulation of a key angiogenesis gene, Delta-like 4 (Dll4).
Rapid Amplification of cDNA Ends (RACE) method was used to identify natural antisense transcripts in the Dll4 gene locus in murine and human endothelial cells, referred to as Dll4 Anti-Sense (Dll4-AS). Messenger RNA (mRNA) levels of Dll4 and Dll4-AS were quantified by real-time PCR. The function of Dll4-AS was investigated by overexpression and knocking down of Dll4-AS.
Dll4-AS comprises of three isoforms that map proximal to the Dll4 promoter region. Expression patterns of Dll4-AS isoforms vary among different endothelial cell lines, but are always congruent with those of Dll4. A dual promoter element in the Dll4 locus has been identified that controls the expression of both transcripts. Both Dll4-AS and Dll4 are sensitive to cellular density in that higher cellular density favors their expression. Exogenous Dll4 stimuli such as VEGF, FGF and Notch signaling inhibitor altered both DLL4-AS and DLL4 expression suggesting co-regulation of the transcripts. Also, knocking down of Dll4-AS results in down-regulation of Dll4 expression. As a consequence, endothelial cell proliferation and migration increases in vitro, and sprout formation increases. The regulation of Dll4 by Dll4-AS was also conserved in vivo.
A novel form of non-coding RNA-mediated regulation at the Dll4 locus contributes to vascular developmental processes such as cell proliferation, migration and sprouting.
Recent findings demonstrate that a new class of RNA arising from intergenic or introns of vascular specific genes participate in the regulation of angiogenesis, the growth of new blood vessels from existing vasculature [1-3]. These RNAs are referred to as non-coding RNAs (ncRNAs) because majority of ncRNAs in the genome do not code for proteins . NcRNAs are classified as long (>200 bp) (lncRNAs) or short (<200 bp) (sncRNAs) based on their sizes . Recent evidence suggests that they are located in the sense (S) or antisense (AS) orientation [6,7] and, to date, the functional significance of these ncRNAs is poorly understood. Previous work from our laboratory identified a non-coding RNA in the antisense direction to the tie1 locus, which participates in the regulation of the tie1 mRNA  during embryonic vascular development. However, we noted that only a small but significant proportion of embryos displayed tie1 loss-of-function phenotype. Therefore, we hypothesized that compared to recessive genes, haploinsufficient genes such as Vegf  and Delta-like4 (Dll4)  are tightly regulated during vascular development by antisense RNA. We focused here on Dll4, an arterial endothelial specific ligand for Notch1 receptor . We investigated whether antisense RNA exists in the Dll4 locus, and whether they had a functional relevance to Dll4 mRNA regulation. Delta-like 4 (Dll4) is an arterial endothelial specific ligand for Notch1 receptor , and is a vascular-specific haploinsufficient gene , in that loss of one copy causes phenotype. Dll4 plays a paramount role in angiogenesis; and altered Dll4 levels during mouse development caused vascular malformations, leading to lethality . In this study, we have identified lncRNAs at the Dll4 locus. They are transcribed anti-sense to Dll4, and therefore, we refer to these transcripts as Delta-like4 antisense (Dll4-AS). Both Dll4 and Dll4-AS transcripts share a common promoter element in the Dll4 genomic locus. Further, we identify that Dll4-AS regulates Dll4 mRNA levels in vitro, and this regulation has functional consequences.
Identification of Dll4-AS
PolyA RNAs were isolated from mouse endothelial cell line, MS1 using a Poly(A)Purist Kit (Life Technologies, AM1916). FirstChoice RLM-RACE Kit (Life Technologies, AM1700) was used to obtain the full length sequences of Dll4-AS. The RACE primers were derived from the cDNA sequence of Gm14207 (Accession No. NR_030683). RACE primers were cctcttcccttaggagtgtgtcctctgt (5′ outer), aggtggcctctggttgtcttcatgt (5′ inner), ctcggcttttcctcatacctc (3′ outer) and tgtccactgtctggttgctc (3′ inner).
Subcellular localization of Dll4-AS
NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific #78833) was used to separate nuclei and cytoplasm of MS1 cells. The separated two parts were subjected to TRIzol extraction, followed by reverse transcription. Xist served as positive control for nuclear compartment and tRNA-Met for cytoplasmic compartment. The primers were Xist-for, tgcgggttcttggtcgatgt, Xist-rev, cgcttgagatcagtgctggc; tRNA-Met-for, ggcccataccccgaaaac, tRNA-Met-rev, acgggaaggatttaaaccaa.
Total RNA from cultivated cells was extracted by TRIzol reagent followed by DNase I treatment for 2 h at 37°C. The DNA-free RNA was further purified using RNAeasy Mini kit (Qiagen, 74104). RNA concentrations were measured by Nanodrop (Thermo Scientific), followed by reverse transcription by SuperScript III (Life Sciences). Quantitative PCR was carried out with SYBR Green I in iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad, 170–9780). The expression levels were normalized to internal βactin or CD31. Primers for mouse βactin, Dll4-AS1, −AS2, −AS3, total Dll4-AS and Dll4 were: βactin-for, ctcttttccagccttccttct, βactin-rev, aggtctttacggatgtcaacg; AS1-for, ttctcaaaaactccgctgct, AS1-rev,ctctgctctttcccctcctc; AS2-for, atccgacgccttaacctttc, AS2-rev,ctccgttctgctcctattgc; AS3-for, cccgaaaccttgacttttca, AS3-rev, ccaccagaggataggagggta; ASt-for, gaggcaataggagcagaacg, ASt-rev, gccaggttgttcagtcaaga; Dll4-for, cagagacttcgccaggaaac, Dll4-rev, actgcagatgacccggtaag. Primers for human CD31, DLL4 and DLL4-AS were: CD31-for, tgaacctgtcctgctccatc, CD31-rev, ccgactttgaggctatcttgg; DLL4-for, actgtgcccgtaacccttg, DLL4-rev, tggagaggtcggtgtagcag; and DLL4-AS-for, agatgccttgtgtgggacta, DLL4-AS-rev, cctctctcaactccaaatcctg.
Promoter reporter gene assay system
DNA fragments mapped to Dll4 promoter regions were cloned into pGL4.14 vector (Promega, E6691) using In Fusion cloning system (Clontech, 638909). pGL4.14 constructs containing different inserts were mixed with pRL-TK Vectors (Promega, E2241) at 20/1 for co-transfecting MS1 cells. Before luciferase activity was determined, the cells were re-plated onto 24-well plate so that the cellular density reached 90% confluence at the time point of assay. Following the addition of 200 μL 1X reporter lysis buffer into each well, the plate was placed at −80°C for 30 min and then equilibrated at room temperature. The cellular lysate was centrifuged at maximum speed for 1 min. Cleared lysates were used to measure luciferase and renilla activity on GloMax® 20/20 Luminometer (Promega, E5331) by Dual-Luciferase Reporter Assay System (Promega, E1910).
Overexpression of Dll4-AS
pTracer™-CMV2 Vector (Life technologies, V885-01) was digested with EcoRV and NotI for sub-cloning Dll4-AS isoforms. Dll4-AS1, −AS2 and -AS3 were amplified from MS1 cDNA using Phusion DNA polymerase and the primers harbored NotI site at the 3′ end. The plasmid contained a separate cassette encoding green fluorescent protein (GFP) -Zeocin expression that allowed for stable selection of transfected cells. Transfection of the plasmids was performed according to the protocol of Lipofecatmine 2000 (Life technologies, 11668027). The cells were selected by Zeocin, and cells overexpressing Dll4-AS were tracked through GFP expression.
Vector-Based miRNA and synthetic siRNA were used to knockdown Dll4-AS expression in both MS1 and EOMA cells. pcDNA6.2-GW/EmGFP-miR (Life technologies, K4936-00) was used to express miRNA targeting the common last exon of all Dll4-AS isoforms. The inside single-stranded DNA oligonucleotides encoding the target pre-miRNA and the complementary oligonucleotides for miR1 are tgctgaggttgttcagtcaagaacctgttttggccactgactgacaggttcttctgaacaacct and cctgaggttgttcagaagaacctgtcagtcagtggccaaaacaggttcttgactgaacaacctc, respectively. Those for miR2 are tgctgctctgattagatccattcaaggttttggccactgactgaccttgaatgtctaatcagag and cctgctctgattagacattcaaggtcagtcagtggccaaaaccttgaatggatctaatcagagc, respectively. The forward and reverse synthetic siRNAs for control, siRNA1 and siRNA2 are ggugagccguguagaguaatt, uuacucuacacggcucacctt, gguaggaggccugugauaatt, uuaucacaggccuccuacctt, ggaggccugugauaagguutt, aaccuuaucacaggccucctt, respectively.
MS1 cells were plated on sterile glass coverslips placed in the wells of a culture plate and allowed to adhere overnight. Cells on coverslips were transfected with siRNAs. 48 h later, the coverslips were removed from the well, washed in TBS [50 mM Tris · HCl (pH 7.4), 150 mM NaCl], and fixed in 4% (wt/vol) paraformaldehyde for 10 min before permeabilization in 0.2% (vol/vol) Triton X-100 for 5 min. Cells were blocked in PBS with 1% goat serum and 0.1% Tween for 1 h at room temperature before staining with goat anti-mouse DLL4 (R&D, AF1389). Following 45 min incubation, cells were washed in TBS, followed by incubation with a fluorescent-conjugated IgG secondary antibody for 30 min in dark. After staining, coverslips were mounted in VectaShield containing DAPI.
Care of the mice during experimental procedures was conducted in accordance with the policies of the Biomedical Resource Center, Medical College of Wisconsin, and the National Institutes of Health guidelines for the care and use of laboratory animals. Protocols had received prior approval from the Medical College of Wisconsin Institutional Animal Care and Use Committee. C57BL/6 mice were obtained from Charles River Laboratories (Franklin, CT). Six day-old C57BL/6 mouse pups were injected intraperitoneally with 1 mg/kg ultrapure LPS (Invivogen, CA) or saline and lungs were harvested after 18 h following sacrifice of animals. RNA was obtained from whole lung using the PureLink RNA kit from Life Technologies (Carlsbad, CA).
Cell proliferation assay
Cell proliferation was performed using an ELISA kit (Roche # 11647229001). 5 × 103 cells were inoculated into 96-well culture plate and cells were allowed to attach for 12 h. siRNA-lipid complexes containing 1 pmol mixed siRNA and 0.3 μl Lipofectamine RNAiMAX was added into each well. Medium was refreshed 48 h later and 10 μl BrdU labeling solution was added into it. 12 h later, the labeling medium was replaced by 200 μl FixDenat and incubated for 30 min at room temperature. The FixDenat was replaced by 100 μl anti-BrdU-POD working solution. 90 min later, the wells were washed 3 times with PBS. 100 μl substrate solution was added into each well. Photometric detection was performed 20 min later by SpectraMax 340PC384 Microplate Reader (Molecular Devices).
Cell migration assay
EOMA cells were plated onto a 6-well plate. After the cells adhered to the plate surface, control or mixed Dll4-AS siRNA were introduced into the cells by Lipofectamine RNAiMAX. 48 h later, the cells were plated onto transwell inserts at 4 × 104 cells/well in 500 μL of medium. The transwell inserts were then inserted into a 24-well plate containing 750 μL of medium. Cells were allowed to migrate at 37°C, 5% CO2 for 2 h. Cells were then fixed at 4% PFA at RT for 20 min, and were further stained for 5 min with crystal violet (Sigma) in 2% ethanol and then rinsed in water. The cells on the upper side of the inserts were removed with a cotton swab, and the cells on the lower side of the inserts that were counted under light microscopy. Data are expressed as the mean ± S.D. of 3 independent assays.
Spheroid sprouting assay
MS1 cells in Dulbecco’s modified Eagle medium (DMEM) were suspended in hanging drops (300 cells/30 μL) on the underside of petridish lids. The hanging drops were incubated for 24 h to form spheroids. Harvested spheroids were suspended in 1.5% collagen gel, and the spheroids-containing collagen gel was rapidly transferred into 96-well plates pre-coated with the same collagen gel and allowed to polymerize at 37°C for 30 min. DMEM containing 30 ng/mL recombinant mouse VEGF was added to the plates to cultivate the cells for 7 days. Sprouting vessels were quantified under microscope by counting the sprouts that had grown out of each spheroid.
Identification and characterization of Dll4-AS
We searched the mouse genome databases for non-coding RNAs at Dll4 locus, and found a predicted gene 14207 (Gm14207, Accession No. NR_030683). A cDNA clone containing Gm14207 was identified from the mouse thymus, and because Dll4 is expressed in both thymus and vasculature , we investigated the expression pattern for Gm14207 in endothelial cells (ECs). RT-PCRs based on the Gm14207 sequence was performed, and PCR products of different sizes were amplified in mouse pancreatic endothelial cell line MS1. Rapid Amplification of cDNA Ends (RACE) identified three transcripts antisense to the Dll4 locus in mouse ECs (Figure 1). We named these transcripts Delta-like 4 antisense1 (Dll4-AS1), Delta-like 4 antisense2 (Dll4-AS2), Delta-like 4 antisense3 (Dll4-AS3) with lengths of 558 bp, 720 bp and 687 bp, respectively. The sequences are deposited in GenBank (Accession numbers: KP171170, KP171171 & KP171172). To localize Dll4-AS transcripts in cellular compartments, we used NE-PER Kit (Thermo Scientific) to separate cytoplasmic and nuclear RNAs, and performed RT-PCR using primers located in the common region (Figure 1A). Dll4-AS transcripts were localized in both cytoplasm and nucleus of mouse ECs (Figure 1B). Subsequently, we examined the expression levels of Dll4-AS and Dll4 in different mouse endothelial cell lines (Bend.3: mouse endothelial cell from cerebral cortex; EOMA: mouse endothelial cell from hemangioendothelioma; MAE: Mouse Aortic Endothelial cell; MBE: Mouse Brain capillary Endothelial cell; MS1: mouse endothelial cell from pancreas; sMHEC: Mouse Heart ECs). We found that Dll4-AS level differs dramatically among the tested cell lines. However, comparing across cell lines the trend is the same in that Dll4-AS levels are congruent with Dll4 (Figure 1C). To identify human DLL4-AS, we searched for transcripts at human DLL4 promoter region in the UCSC Genome Browser. Item 3619762 of Affymetrix Exon Array from ENCODE/UW was retrieved and validated by RT-PCR. The transcript was extended to 768 bp by tiling PCR (Additional file 1: Figure S1).
Dll4-AS shares a common promoter with Dll4
To identify the genomic element that drives Dll4-AS expression, we cloned DNA fragments near the transcription start site of Dll4-AS into a promoter reporter vector, pGL4.14 (Figure 2A). Those fragments were placed in different directions, corresponding to either Dll4-AS or Dll4 transcription into the vector, and co-transfected with renilla construct into MS1 cells. Fragments A and A’ were in the antisense (Dll4-AS) direction, while fragments B and B’ were in the Dll4 sense direction. Lysates were generated, and luciferase gene readouts were measured. Fragment B and B’ showed the most activity when compared to A and A’. Interestingly, A’ and B’ is the same fragment in opposite direction, and show promoter activity in both directions. These results indicate that the promoter of Dll4-AS is the same region as that of Dll4 (Figure 2B), and imply that the two transcripts share the same promoter region, and drives RNA transcription in both directions.
Dll4-AS expression is concomitant with Dll4 mRNA expression
Because Notch-Delta signaling pathway has been extensively implicated in cell-cell contact signaling, we investigated the expression of Dll4-AS and Dll4 mRNA levels in different confluent states of MS1 cells. Cells in 100% confluent state (dense) showed high levels of Dll4-AS, and Dll4 mRNA levels, and this increase was observed as the confluency increased from 4-100%. Consistently, we observed three things. First, that Dll4 expression is a log higher than Dll4-AS. Second, differences are observed within each of the three Dll4-AS transcripts across confluency stages, and third that both RNA levels change positively (Figure 3A). To investigate whether Dll4 and Dll4-AS RNAs are co-regulated, we treated 90% confluent MS1 cells with increasing concentrations of DAPT, a notch inhibitor (Figure 3B), or human umbilical vein (Figure 3C) or coronary artery (Figure 3D) ECs with growth factors VEGF and FGF. In each case, we observed that when DLL4 RNA level increases or decreases, the DLL4-AS levels increase or decrease respectively.
To confirm these findings in vivo, we performed experiments in the lung tissues in mice. Mice were treated with lipopolysaccharide (LPS) and lung tissues were harvested to analyze levels of Dll4 and Dll4-AS RNA. LPS is known to induce angiogenesis and modify notch signaling [12,13]. Lung tissues isolated from LPS-treated neonatal mice showed increase in both Dll4 and Dll4-AS RNA levels (−2 and −3) when compared to control mice (Figure 3E). The increase in Dll4-AS is less than that of Dll4, which is consistent with the data from cultured cells. These results suggest that Dll4AS regulation occurs both in vitro and in vivo, and the regulation is conserved across humans and mice presumably by a set of factors that bind at the common promoter region.
Dll4-AS regulates Dll4 expression
We investigated using loss-of-function approaches, the effect of Dll4-AS on Dll4 RNA levels in ECs. We used pcDNA6.2-GW/EmGFP-miR vector designed to express artificial microRNAs (miRNAs). Two artificial miRNAs that showed 100% homology to the target sequence and targeting the common regions of Dll4-AS isoforms were designed. MS1 cells transfected with the two artificial miRNAs successfully decreased Dll4 mRNA level (Figure 4A). To exclude the off-target possibility of the miRNAs, we used synthetic short hairpin silencing RNAs (siRNA) oligonucleotides targeting the common region of Dll4-AS isoforms. When the siRNAs were transfected into MS1 cells, Dll4-AS expression dropped 60%. Similarly, Dll4 mRNA decreased roughly 40% (Figure 4B), which was further validated at the protein level by immunocytochemistry (Figure 4C). In gain-of-function experiments, we overexpressed individual Dll4-AS in MS1 cells. Western blot analysis of MS1 cell lysates showed that Dll4-AS1 and -AS3 up regulated the DLL4 protein levels (Figure 4D).
Dll4-AS regulates angiogenesis
Because Dll4-AS affects Dll4 mRNA expression, we postulate that modulating Dll4-AS levels in ECs should affect EC phenotype. We focused on cell proliferation and migration, two phenotypes associated with tip vs. stalk cell formation where Dll4 is known to participate in . We compared the modulations of Dll4-AS in two cell lines namely MS1 and hemangioendothelioma (EOMA) cell line. EOMA cells are extensively used for vascular anomaly research, a condition associated with aberrant DLL4 signaling . We performed BrdU-based proliferation assay in Dll4-AS silenced MS1 cells, and observed an increase in cellular proliferation (Figure 5A), which was also observed in EOMA cell line (Figure 5B). Intriguingly, Dll4-AS silenced EOMA cells showed increased migration to serum stimulus in the Boyden chamber assay (Figure 5C). To investigate Dll4-AS influence on sprout formation and branching, we generated cellular spheroids using MS1 cells. The spheroids were embedded in collagen gel and cultured under VEGF stimulation conditions. The sprouting vessels that emerged from the spheroids were analyzed at day 7. On average, 3.9 sprouts emerged from the spheroids of wild type MS1 cells, whereas 5.7 sprouts emerged from Dll4-AS knockdown [Figure 5D and E] MS1 cells. This data implies that similar to Dll4, Dll4-AS also restricts endothelial sprouting. These results collectively suggest that down-regulation of Dll4-AS and in turn Dll4 impairs EC proliferation and migration responses, concepts associated with non-productive angiogenesis observed previously in Dll4 knockout mice .
In this study, we have identified lncRNAs at the Dll4 locus. The salient features of this study are: (a) Identification of three isoforms of Dll4-AS in murine ECs that are transcribed in the antisense direction to Dll4, and share the last exon; (b) Genomic locus of Dll4 contains cis elements that are responsible for the dual transcription of Dll4 and Dll4-AS; (c) Co-regulation of Dll4 and Dll4-AS transcripts is observed in that loss of Dll4-AS affects Dll4 mRNA level in vitro and in vivo; and (d) Down-regulation of Dll4-AS (and in turn Dll4) functionally impairs EC proliferation and migration, and enhances sprout formation. These results collectively implicate a new level of regulation at the Dll4 gene locus in vascular development.
LncRNAs are a new class of regulators involved in genome organization and gene expression, especially in the process of cell differentiation and organ development . In contrast to sncRNAs such as miRNAs, which target multiple coding sequences, lncRNAs usually target nearby genes [2,18]. Haploinsufficient genes like Dll4 undergo tight regulation, and gene dosage is carefully monitored because Dll4 is a key modulator of angiogenic sprouting and branching processes, critical events associated with physiological and pathological angiogenesis. Regulation of Dll4 clearly occurs at the transcriptional and post-transcriptional levels . Our report here proposes an additional layer of regulation to include lncRNAs-mediated Dll4 regulation. Three lncRNA isoforms of Dll4-AS were identified with expression levels for each varying greatly across multiple cell types. The rationale for mutliple isoforms at this locus is unclear. Of the three isoforms of Dll4-AS, only Dll4-AS1 overlaps with Dll4. We hypothesize that these RNAs are part of the checks and balances in the system for control of haploinsufficient gene expression.
Antisense ncRNAs arising from promoter regions can be classified into two categories according to their location . The first category is composed of antisense ncRNAs overlapping with the corresponding mRNAs like Dll4-AS1. These antisense ncRNAs have been shown to down-regulate the corresponding mRNAs via the formation of ncRNA-mRNA duplexes . The second category is antisense ncRNAs starting from regions upstream of the transcription start sites (TSSs) of the corresponding mRNAs, i.e., Dll4-AS2 and -AS3. These antisense ncRNAs have been shown to functionally up-regulate the corresponding mRNAs via epigenetic mechanisms . However, location of lncRNAs do not strictly dictate up or down regulation of cognate transcript. In our case, in MS1 and EOMA cells, Dll4-AS2 and -AS3 expression are highest compared to Dll4-AS1. Whether this selective up regulation of the AS isoforms is of functional consequence is yet to be determined. This selective up regulation was also noticed in the LPS-treated lung samples where AS2 and AS3 levels were up along with Dll4. Intriguingly, in overexpression experiments, Dll4-AS1 and AS3 transfected MS1 cells showed increased DLL4 protein compared to Dll4-AS2. Our results collectively suggest that selective combinatorial expression of Dll4-AS specific isoforms in cells and tissues control the expression of Dll4.
Genome locus of Dll4 contains a number of cis elements, which allow transcription factors to bind and control the expression of Dll4 . Dll4-AS shares a common promoter region with Dll4, implicating a co-regulatory mechanism for both RNAs. Gene placement in a “head-to-head” fashion like that of Dll4 and Dll4-AS is an ancient and conservative gene organization structure. The intergenic region between Dll4 and Dll4-AS serves as a shared promoter, which drives the expression of the two genes toward opposite directions. This RNA Pol II-mediated process occurs in almost equal proportion in both directions . The promoter sequence ultimately decides the dominant transcriptional direction , resulting in more abundant sense transcripts than antisense transcripts . This is consistent in regards to the expression levels of Dll4-AS and Dll4, with more abundant Dll4 mRNA observed in qPCR in cells, and also in reporter assays where the sense promoter direction is more active than the antisense direction. Most bidirectional promoters act as inseparable functional units that coordinately regulate the transcription of both genes , which is also consistent with our findings. The in vivo experiments on LPS-treated lung samples also confirm the co-regulatory aspects of this regulation.
Transcriptional correlation prognosticates functional association , so the function of Dll4-AS is likely to be pertinent to that of Dll4. In fact, both Dll4-AS and Dll4 are co-expressed in ECs and show a positive correlation. Correlations between bidirectional transcripts could be positive or negative depending on differences in the cellular status . Generally, positively correlated transcripts function in the same signaling pathway, and are coregulated in a common window of the cell cycle to respond to inductive signals [29-31]. Therefore, it is not surprising that down regulation of Dll4-AS downregulates Dll4. Further, down regulation of Dll4 in mouse causes a hypersprouting phenotype . However, these sprouts are non-functional, which is referred to as non-productive angiogenesis . Similarly, when Dll4 is downregulated due to loss of Dll4-AS, the ECs are hyperproliferative and hypermigratory, concepts that support non-productive angiogenesis. Sprouting was enhanced from Dll4-AS siRNA treated MS1 cells further confirming the similar functional role for Dll4-AS and Dll4 in angiogenesis. Whether this regulation leads to differences in tip vs. stalk cell specification is unknown because Dll4-Notch is known to actively participate in this process . Similarly, Dll4-AS and Dll4 levels are affected by VEGF stimulation implying that Dll4-AS regulation of Dll4 may participate in the VEGF-Notch cross talk pathway during angiogenesis. The factors that govern the regulation of the Dll4-AS transcript expression, and the role of antisense RNA regulation in specific processes of angiogenesis are all active areas of investigation in the lab.
In summary, we report here the identification of three lncRNAs in the antisense direction in the Dll4 locus. These antisense RNAs are co-regulated with Dll4 RNA using a common genomic element. Downregulation of Dll4-AS affects Dll4 levels in ECs, which in turn causes functional changes to the phenotype of ECs. We conclude that Dll4-AS regulation of Dll4 is a novel mechanism of gene expression modulation, which has functional implications in vascular development.
Long non-coding RNAs
Vascular endothelial growth factor
Fibroblast growth factor
Li K, Blum Y, Verma A, Liu Z, Pramanik K, Leigh NR, et al. A noncoding antisense RNA in tie-1 locus regulates tie-1 function in vivo. Blood. 2010;115:133–9.
Michalik KM, You X, Manavski Y, Doddaballapur A, Zornig M, Braun T, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res. 2014;114:1389–97.
Bell RD, Long X, Lin M, Bergmann JH, Nanda V, Cowan SL, et al. Identification and initial functional characterization of a human vascular cell-enriched long noncoding RNA. Arterioscler Thromb Vasc Biol. 2014;34:1249–59.
Guttman M, Russell P, Ingolia NT, Weissman JS, Lander ES. Ribosome profiling provides evidence that large noncoding RNAs do not encode proteins. Cell. 2013;154:240–51.
Prasanth KV, Spector DL. Eukaryotic regulatory RNAs: an answer to the ‘genome complexity’ conundrum. Genes Dev. 2007;21:11–42.
He Y, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW. The antisense transcriptomes of human cells. Science. 2008;322:1855–7.
Rosok O, Sioud M. Systematic identification of sense-antisense transcripts in mammalian cells. Nat Biotechnol. 2004;22:104–8.
Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438:937–45.
Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A. 2004;101:15949–54.
Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 2000;14:1313–8.
Benedito R, Duarte A. Expression of Dll4 during mouse embryogenesis suggests multiple developmental roles. Gene Expr Patterns. 2005;5:750–5.
Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-terminal kinase. Blood. 2003;102:1740–2.
Kim MY, Park JH, Mo JS, Ann EJ, Han SO, Baek SH, et al. Downregulation by lipopolysaccharide of Notch signaling, via nitric oxide. J Cell Sci. 2008;121:1466–76.
Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol. 2010;12:943–53.
ZhuGe QZM, Zheng W, Yang GY, Mao X, Xie L, Chen G, et al. Notch-1 signalling is activated in brain arteriovenous malformations in humans. Brain. 2009;132:11.
Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444:1032–7.
Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev Genet. 2014;15:423–37.
Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23:1494–504.
Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol. 2003;23:14–25.
Uesaka M, Nishimura O, Go Y, Nakashima K, Agata K, Imamura T. Bidirectional promoters are the major source of gene activation-associated non-coding RNAs in mammals. BMC Genomics. 2014;15:35.
Ebralidze AK, Guibal FC, Steidl U, Zhang P, Lee S, Bartholdy B, et al. PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev. 2008;22:2085–92.
Tomikawa J, Shimokawa H, Uesaka M, Yamamoto N, Mori Y, Tsukamura H, et al. Single-stranded noncoding RNAs mediate local epigenetic alterations at gene promoters in rat cell lines. J Biol Chem. 2011;286:34788–99.
Sacilotto N, Monteiro R, Fritzsche M, Becker PW, Sanchez-Del-Campo L, Liu K, et al. Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development. Proc Natl Acad Sci U S A. 2013;110:11893–8.
Core LJ, Waterfall JJ, Lis JT. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science. 2008;322:1845–8.
Schmidt C, Fischer G, Kadner H, Genersch E, Kuhn K, Poschl E. Differential effects of DNA-binding proteins on bidirectional transcription from the common promoter region of human collagen type IV genes COL4A1 and COL4A2. Biochim Biophys Acta. 1993;1174:1–10.
Trinklein ND, Aldred SF, Hartman SJ, Schroeder DI, Otillar RP, Myers RM. An abundance of bidirectional promoters in the human genome. Genome Res. 2004;14:62–6.
van Noort V, Snel B, Huynen MA. Predicting gene function by conserved co-expression. Trends Genet. 2003;19:238–42.
Li YY, Yu H, Guo ZM, Guo TQ, Tu K, Li YX. Systematic analysis of head-to-head gene organization: evolutionary conservation and potential biological relevance. PLoS Comput Biol. 2006;2:e74.
Battistoni A, Guarguaglini G, Degrassi F, Pittoggi C, Palena A, Di Matteo G, et al. Deregulated expression of the RanBP1 gene alters cell cycle progression in murine fibroblasts. J Cell Sci. 1997;110(Pt 19):2345–57.
Hansen JJ, Bross P, Westergaard M, Nielsen MN, Eiberg H, Borglum AD, et al. Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter. Hum Genet. 2003;112:71–7.
Heikkila P, Soininen R, Tryggvason K. Directional regulatory activity of cis-acting elements in the bidirectional alpha 1(IV) and alpha 2(IV) collagen gene promoter. J Biol Chem. 1993;268:24677–82.
Siekmann AF, Lawson ND. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature. 2007;445:781–4.
The authors thank members of the Developmental Vascular Biology Program for their critical input and suggestions, Dr. Auerbach at the University of Wisconsin-Madison for providing murine endothelial cell lines during the course of this work. This work was supported by a postdoctoral fellowship (K.L.) from American Heart Association ( POST4180008) and grants from National Institutes of Health [1R01HL102745-01 & 1R01HL112639-01] (R.R.). T.C. is supported by funds from Department of OBGYN. VS is partly supported by the CTSI of Southeast Wisconsin 8KL2TR000056 grants.
The authors declare that they have no competing interests.
KL designed and performed experiments, interpreted data, and wrote parts of the manuscript. TC designed and performed experiments, interpreted data, and edited the manuscript. VP designed and performed experiments, and interpreted data. CK designed and performed experiments, and interpreted data. VS contributed novel reagents, provided intellectual input and edited the manuscript. RR provided intellectual input, direction in experimental design, provided resources and wrote the manuscript. All authors read and approved the final manuscript.
Schematic representation of DLL4 locus in Homo sapiens chromosome 15, GRCh38 Primary Assembly. DLL4 mRNA starting from 40929333 is shown in red boxes; DLL4-AS starting from 40927667 and ending at 40926900 is shown in a blue box.